Business Context and Reporting Period
This Form 8-K was filed by Oramed Pharmaceuticals Inc. on May 13, 2019. The report discloses a material change in executive leadership, specifically the appointment of a new Chief Financial Officer.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on personnel changes and compensation arrangements.
Material Changes
- Executive Appointment: The Company appointed Avi Gabay, 34, as Chief Financial Officer, Treasurer, and Secretary, effective June 1, 2019.
- Compensation: Mr. Gabay's gross monthly salary is set at NIS 35,000. He will receive a company car and is eligible for bonuses and equity grants at the discretion of the Board of Directors and Compensation Committee.
- Employment Structure: Mr. Gabay will be employed by Oramed Ltd., the Company's wholly-owned Israeli subsidiary.
Outlook, Risks, and Management Commentary
The filing contains no forward-looking guidance, risk factors, or management commentary regarding business operations or financial outlook. It notes that Mr. Gabay is not a party to any transactions disclosable under Item 404 of Regulation S-K and that the Company expects to enter into a standard indemnification agreement with him.
Investor Verification Checklist
- Verify the effective date of the CFO appointment (June 1, 2019).
- Confirm the currency and amount of the new CFO's base salary (NIS 35,000/month).
- Review the Company's subsequent filings for details on the specific equity grants and bonus structures to be determined by the Board.
- Check for any prior filings regarding the departure of the previous CFO or Treasurer.